22 November 2023 - Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College of Asthma, Allergy and Immunology Meeting demonstrate dose dependent, clinically meaningful desensitisation responses and a favourable safety profile in paediatric patients allergic to qualifying foods.

Alladapt Immunotherapeutics today announced that ADP101, its investigational multi-food oral immunotherapy designed to simultaneously treat allergy to one or more of the world’s most significant food allergens, received fast track designation from the US FDA.

Read Alladapt Immunotherapeutics press release